Background Only clinically validated HPV assays can be accepted in cervical cancer
screening. Objectives To update the list of high-risk HPV assays that fulfil the 2009 …

Several countries are in the process of switching to high-risk human papillomavirus (hrHPV)
testing for cervical cancer screening. Given the multitude of available tests, validated assays …

OBJECTIVE: This is a meta-analysis of studies comparing HPV testing to cytology with
regard to their accuracy in the detection of underlying high grade cervical intraepithelial …

Background Testing for high-risk HPV is more effective in primary cervical cancer screening
than the cytological examination of a Pap smear. Separate genotyping may be useful for …

High-risk human papillomavirus (hrHPV) testing is now being introduced as a potential
primary screening test for improved detection of cervical precancer and cancer. Current US …

Commercial molecular tests for human papillomaviruses (HPV) are invaluable diagnostic
tools in cervical carcinoma screening and management of women with cervical …

Objective Previous findings from cross-sectional studies have shown human papillomavirus
(HPV) testing to be more sensitive than cytology testing for primary cervical screening. This …

Background Cervical cancer screening tests that identify DNA of the main causal agent, high-
risk human papillomavirus (HPV) types, are more protective than cervical cytology. We …

Background Cervical cancer screening has traditionally been based on cervical cytology.
Given the aetiological relationship between human papillomavirus (HPV) infection and …

Objectives ATHENA evaluated the cobas HPV Test as the primary screen for cervical cancer
in women≥ 25 years. This reports the 3-year end-of-study results comparing the …